ABSTRACT This pooled analysis evaluated the relationship of isavuconazole and voriconazole MICs of Aspergillus pathogens at baseline with all-cause mortality and clinical outcomes following treatment with either drug in the SECURE and VITAL trials. Isavuconazole and voriconazole may have had reduced efficacy against pathogens with drug MICs of Ն16 g/ml, but there was no relationship with clinical outcomes in cases where the MIC was Ͻ16 g/ml for either drug.
I
nvasive fungal diseases (IFD) are serious medical conditions (1) (2) (3) . For example, mortality rates for invasive aspergillosis (IA) at 6 weeks are approximately 20% (4) . Treatment guidelines from the Infectious Diseases Society of America and the European Conference on Infections in Leukemia recommend voriconazole as a first-line agent for IA (5) (6) (7) . On the basis of the results of the SECURE and VITAL phase 3 trials (8, 9) , isavuconazole was approved by the U.S. Food and Drug Administration for the treatment of adults with IA or invasive mucormycosis and by the European Medicines Agency for treatment of adults with IA or with mucormycosis when amphotericin B is not appropriate. Isavuconazole has also now been included in guidelines as an alternative first-line agent (5) (6) (7) . Clinical breakpoints for isavuconazole have now been defined by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for several Aspergillus spp. (10) .
This analysis describes the relationships of MICs of isavuconazole and voriconazole against Aspergillus pathogens at baseline in pooled data from the SECURE (8) and VITAL trials (11), which compared isavuconazole (200 mg [administered as 372 mg prodrug dose] orally or intravenously every 8 h for 48 h, then once daily) and voriconazole (6 mg/kg intravenously twice daily on day 1, 4 mg/kg intravenously twice daily on day 2, then intravenously 4 mg/kg twice daily or orally 200 mg twice daily from day 3 onwards) for the primary treatment of IFD caused by Aspergillus spp. and other filamentous fungi, and efficacy of isavuconazole for patients with IA and renal impairment or with other rare IFDs, respectively.
Antifungal susceptibilities were tested (Clinical and Laboratory Standards Institute [CLSI] and EUCAST methods) (12, 13) in 96 Aspergillus sp. isolates (morphologically and molecularly confirmed [14, 15] ) obtained at baseline. For all pathogens from patients treated with isavuconazole (n ϭ 55 patients; mean age [standard deviation {SD}] 49.5 [17.5] years; 71 Aspergillus samples), the CLSI and EUCAST MIC values were the same (MIC 50 , 1 g/ml; MIC 90 , 4 g/ml). Furthermore, the ranges of MICs were comparable (CLSI, 0.25 to 32 g/ml; EUCAST, 0.12 to 32 g/ml).
The MIC 50 and MIC 90 for pathogens from patients treated with voriconazole (n ϭ 23 patients; mean age [SD] 53.1 [16.1] years; 25 Aspergillus samples) were 1 g/ml and 2 g/ml, respectively, as determined using either CLSI or EUCAST methods. The ranges of MICs were 0.25 to 2 (CLSI) and 0.25 to 16 (EUCAST) g/ml. In summary, isavuconazole and voriconazole displayed potent in vitro activity against the majority of Aspergillus spp., with MICs consistent with those recently reported elsewhere (16) (17) (18) (19) (20) .
All-cause mortality (ACM) through day 42 was assessed in all patients with proven, probable, or possible IFD who received at least one dose of study drug (Table 1; seen also Table S1 in ths supplemental material). Among isavuconazoletreated patients (Aspergillus spp. only), the ACM rates associated with pathogens having drug MICs of Յ1 g/ml were 12.1% (4/33; CLSI) and 9.7% (3/31; EUCAST), whereas the ACM rates associated with pathogens having drug MICs of Ͼ1 g/ml were 12.5% (2/16; CLSI) and 16.6% (3/18; EUCAST). Among voriconazole-treated patients (Aspergillus spp. only), the ACM rates associated with pathogens having drug MICs of Յ1 g/ml were 23.5% (4/17; CLSI) and 27.8% (5/18; EUCAST), whereas the ACM rates associated with pathogens having drug MICs of Ͼ1 g/ml were 60% (3/5; CLSI) and 50% (2/4; EUCAST). With the exception of one patient in the isavuconazole group who was infected with multiple fungal species, all patients in both treatment groups infected with Aspergillus spp. with drug MICs of Ն16 g/ml (n ϭ 2 for isavuconazole by either CLSI or EUCAST; n ϭ 1 for voriconazole by EUCAST only) died by day 42. For patients with Aspergillus-only infections, ACM at day 42 was generally higher with voriconazole than with isavuconazole ( Fig. 1 ) (Table 1; see also Table S1 ); however, the study was underpowered to enable a statistical comparison between the groups.
The overall response (composite of clinical, mycological, and radiological [where relevant; see Table S2 ] responses at end of treatment [EOT] in patients with proven or probable IFD, as assessed by blind-data review committee) (21) was also investigated. Among isavuconazole-treated patients infected with pathogens (Aspergillus spp. only) with drug MICs of Յ1 g/ml, overall successful responses were observed in 45.5% (15/33; CLSI) and 45.2% (14/31; EUCAST), whereas in cases of pathogens with drug MICs of Ͼ1 g/ml, overall successful responses were observed in 43.8% (7/16; CLSI) and 44.4% (8/18; EUCAST) ( Table 2 ) (see also Fig. S1 and Table S3 in the supplemental material). Among voriconazole-treated patients infected with pathogens (Aspergillus spp. only) with drug MICs of Յ1 g/ml, overall successful responses were observed in 47.1% (8/17; CLSI) and 44.4% (8/18; EUCAST), whereas the overall successful responses observed for those whose pathogens had drug MICs of Ͼ1 g/ml were 20.0% (1/5; CLSI) and 25.0% (1/4; EUCAST).
These analyses of primarily wild-type isolates from the SECURE and VITAL trials suggest that a clearly defined relationship between in vitro susceptibility and clinical outcomes may not be detectable below the epidemiological cutoff value of Յ1 g/ml (CLSI) (22) or Յ2 g/ml (EUCAST) for most common Aspergillus spp. (23) . Moreover, this analysis was limited by the small number of isolates, which prevented statistical analysis of the relationship between susceptibility and outcomes and precluded comments on suboptimal outcomes associated with high MICs. Using clinical data to verify the adequacy of current breakpoints would require much larger studies and enrollment of patients with infections by strains with drug MICs higher than the breakpoint, the latter of which would not be ethically tenable. 
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